“Friday's First Moves: MRNA Cancer Vaccine Trial Leaks, DECK Earnings, NCLH Downgrade”Cited source: JPMorgan Chase
$NCLHBearish
AI summary · JPMorgan downgraded NCLH to underweight and cut its target to $11 before earnings, expecting a decline on 2027 demand and cost uncertainty and European exposure, where approximately 85% of European travel customers are from the US; even if earnings beat, cruise and international travel demand remains unclear.
Let's talk about the downgrade of the Norwegian company. I have been downgraded by JPMorgan Chase. They downgraded its rating to "underweight" and lowered the stock price target to $11.
This was before the announcement of its profits. Therefore, they expect a drop from here. We are currently experiencing a decline of more than 5.5 percent .